Trial Profile
BRIDGE Trial: Phase II Trial of durvalumaB and chemotheRapy Induction Followed by Durvalumab and Radiotherapy in larGe volumE Stage III NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BRIDGE
- 18 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2023 This trial has been completed in France, according to European Clinical Trials Database record.
- 30 May 2022 Status changed from not yet recruiting to recruiting.